Search

Your search keyword '"Walker, Scott E."' showing total 193 results
Start Over Author "Walker, Scott E."
193 results on '"Walker, Scott E."'

14. Supplemental Material2 - Supplemental material for Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults

Author

Patel, Priya, Nathan, Paul C, Walker, Scott E, Zupanec, Sue, Volpe, Jocelyne, and L Lee Dupuis

Subjects
FOS: Clinical medicine, fungi, biochemical phenomena, metabolism, and nutrition, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supplemental Material2 for Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults by Priya Patel, Paul C Nathan, Scott E Walker, Sue Zupanec, Jocelyne Volpe and L Lee Dupuis in Journal of Oncology Pharmacy Practice

Published
2019
Full Text
View/download PDF

22. Stability of extemporaneously compounded temozolomide 10 mg/mL suspensions in Oral Mix SF® in glass and plastic bottles and plastic syringes.

Author

Lingertat-Walsh, Karen, Weilnau, JoEllen, Cober, M Petrea, Ostrenga, Andrew, Poon, Betsy, Sales, Pacita, Law, Shirley, Dupuis, L Lee, and Walker, Scott E

Subjects
CONFIDENCE intervals, DRUG stability, DOSAGE forms of drugs, DRUG storage, ORAL drug administration, SUSPENSIONS (Chemistry), TEMPERATURE, DESCRIPTIVE statistics, TEMOZOLOMIDE
Abstract

Background: Temozolomide oral suspension is not commercially available. Objective: To evaluate the stability of three temozolomide 10 mg/mL suspensions prepared in Oral Mix SF® in three container types stored at 4°C and 23°C. Methods: Using commercial capsules, three separate batches of three different temozolomide 10 mg/mL formulations (Oral Mix SF® with PK-30; PK-30 and citric acid; and neither PK-30 nor citric acid) were made and stored in three container types (amber glass bottles, amber polyethylene terephthalate bottles, and polypropylene oral syringes). The aliquots in each container type were stored protected from light, half at 25°C and half at 4°C. On study days 0, 5, 8, 14, 21, 28, 35, 42, and 56, physical properties of samples from each container type at each temperature were assessed, and the temozolomide concentration was determined using a stability-indicating method. The beyond-use-date (time to achieve 90% of initial concentration calculated using the lower limit of the 95% confidence interval of the observed degradation rate) was calculated. Results: Samples stored at 25°C turned from white to orange within seven days. Temozolomide crystals were observed in all samples. Concentration changes due to study day and temperature (p < 0.001) were observed but not due to container (p = 0.991) or formulation (p = 0.987). The beyond-use-date of all formulations in all container types was 56 days at 4°C and 6 days at 23°C. Conclusions: We recommend that these temozolomide 10 mg/mL formulations be stored at 4°C and be assigned a beyond-use-date of 30 days. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

25. Impact of a Comprehensive Antimicrobial Stewardship Program on Institutional Burden of Antimicrobial Resistance: A 14-Year Controlled Interrupted Time-series Study.

Author

Peragine, Christine, Walker, Sandra A N, Simor, Andrew, Walker, Scott E, Kiss, Alexander, and Leis, Jerome A

Subjects
ANTI-infective agents, AUDITING, CONFIDENCE intervals, CROSS infection, DRUG resistance in microorganisms, MULTIDRUG resistance, POISSON distribution, PUBLIC health, REGRESSION analysis, TIME series analysis, EVALUATION of human services programs, STATISTICAL models, DESCRIPTIVE statistics, ANTIMICROBIAL stewardship
Abstract

Background Antimicrobial resistance (AMR) constitutes an international public health threat widely believed to result from excessive antimicrobial use (AMU). Numerous authorities have recommended antimicrobial stewardship programs (ASPs) to curb the selection of AMR, but there is a lack of data confirming this benefit. Methods A controlled interrupted time-series study spanning 14 years was performed to assess impact of a comprehensive hospital-based ASP that included pharmacist-led audit and feedback on institutional AMR. Patient-level microbiologic and AMU data were obtained from October 2002 to September 2016. Poisson regression models were used to identify changes in the incidence and trend of hospital-acquired (HA) antibiotic-resistant organisms (AROs) and multidrug-resistant organisms (MDROs). Changes in community-acquired (CA)–ARO, CA-MDRO, and inpatient AMU were assessed as controls and process outcomes. Results Statistically significant shifts in AMU, HA-ARO, and HA-MDRO trends coinciding with ASP implementation were observed, corresponding with a 9% reduction in HA-ARO burden (incidence rate ratio [IRR], 0.91 [95% confidence interval {CI},.83–.99]; P  = .03) and a 13% reduction in HA-MDRO burden (IRR, 0.87 [95% CI,.73–1.04]; P  = .13) in the intervention period. In contrast, CA-ARO and CA-MDRO incidence continued to rise, with 40% (IRR, 1.40 [95% CI, 1.28–1.54]; P  < .0001) and 68% (IRR, 1.68 [95% CI, 1.57–1.82]; P  < .0001) increases in burden found, respectively. Conclusions Implementation of a comprehensive ASP resulting in reduced AMU was associated with a significant reduction in institutional AMR, even though community AMR increased during the same period. These results confirm that ASPs play an important role in the fight against AMR. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

31. Irreversible monoamine oxidase inhibitors revisited

Author

Shulman, Kenneth I. and Walker, Scott E.

Subjects
Antidepressants, Tricyclic, Oxidases, Health, Psychology and mental health
Abstract

As with many psychiatric drugs, the discovery of irreversible MAOIs was serendipitous. While being used as an antitubercular agent in the 1950s, iproniazid--a derivative of the hydrazine compound isocarboxazid--was observed [...]

Published
2012

33. Tuberculosis : Risk Factors, Drug Resistance and Treatment

Author

Martin, David F., Walker, Scott E., Martin, David F., and Walker, Scott E.

Subjects
Tuberculosis
Abstract

The current resurgence of tuberculosis (TB) is being sustained and fueled by the increasing incidence of resistance of M. tuberculosis strains to the most-effective (first-line) anti-TB drugs and association of active TB disease with concomitant human immunodeficiency virus (HIV) infection or other underlying immunosuppressive conditions such as diabetes. In this book, the authors study the risk factors, drug resistance data and treatment methods for tuberculosis. Topics discussed include the global burden of TB and its public health crisis; new medicines to treat TB; rapid microcalorimetric detection of TB; meta-analysis and risk factors for tuberculosis susceptibility; Type 2 diabetes as a risk factor for TB; and elucidating the action mode of the bi-substrate InhA inhibitors as anti-tuberculosis agents through molecular dynamics simulations.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results